teniposide
Drug data last refreshed 17h ago · AI intelligence enriched 4w ago
VUMON (teniposide) is an injectable semisynthetic epipodophyllotoxin approved in 1992 for treating acute lymphoblastic leukemia (ALL) and small cell lung cancer. It works as a topoisomerase II inhibitor, stabilizing DNA-topoisomerase II complexes to induce apoptosis in rapidly dividing cancer cells.
With LOE approaching and competitive pressure at 30%, the commercial team is likely consolidating resources and planning transition strategies, signaling potential restructuring or headcount shifts in sales and marketing.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
VUMON offers limited career growth opportunities given its LOE-approaching status and lack of linked job openings. Roles on this product are primarily defensive, focused on maximizing remaining market share and managing the transition away from the brand.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.